Synopsis: 

Tariq Kassum, M.D. is the CEO of Celsius Therapeutics, a company pioneering new precision medicines in inflammatory disease by harnessing the power of single-cell RNA sequencing and human biology at scale. Tariq shares his unique journey from med school, to working in Wall Street as a biotech investment banker and stock analyst, to the corporate side working at Millennium Pharmaceuticals and Takeda, and finally the innovative biotech world. He discusses the importance of learning to adapt to each environment in order to remain productive and successful, and building meaningful relationships with coworkers and mentors. He also talks about what it will take for the biopharma executive of the future to be successful.  

Biography: 
Tariq Kassum brings 20 years of experience in corporate development, strategy and business leadership to Celsius. He joined the company in 2019 from Obsidian Therapeutics, where he was a co-founder and served as chief operating officer and head of corporate development. During this time, Tariq helped build Obsidian into a leading platform technology company and played a central role in the company’s strategic partnership with Celgene. Prior to Obsidian, Tariq spent seven years with Millennium Pharmaceuticals and Takeda, most recently as vice president, business development and strategy for Takeda Oncology, responsible for transactions, collaborations, alliance management and strategic planning. Before that, he led Takeda’s global corporate development efforts, where he managed multiple acquisitions and divestitures in the U.S. and internationally. He was also part of the business development team at Millennium Pharmaceuticals.

Prior to Takeda, Tariq was an analyst covering healthcare equities for institutional investment firms, where he led scientific due diligence and investment decisions on numerous companies and pharmaceutical compounds across multiple therapeutic areas. He began his career as an investment banker with CIBC World Markets, serving clients in the biotechnology and specialty pharmaceuticals industries.

A new vision in inflammatory disease: RNAseq led precision medicine, Tariq Kassum, CEO, Celsius Tx

Dr Thomas Cassini explains how the Undiagnosed Diseases Network group used advanced sequencing techniques to clarify the genotype in a child with an unusual phenotype for mitochondrial trifunctional protein deficiency.

Mitochondrial trifunctional protein deficiency caused by a deep intronic deletion leading to aberrant splicing
Thomas Cassini, et al
https://doi.org/10.1002/jmd2.12459

Shortcast: TFP deficiency caused by a deep intronic deletion leading to aberrant splicing

Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.

JIMD Podcasts is home to the Journal of Inherited Metabolic Disease podcast and the JIMD Shortcast. We're also proud to showcase Metabolic Mysteries and the new Footprints in IMD podcast.

New tracks tagged #RNAseq